Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles–mumps–rubella–varicella vaccine during the second year of life: An open, randomized controlled trial

Meningococcal Vaccines

“…MenACWY-TT aşısının çocuk, adolesan, erişkin ve 55-103 yaş arası popülasyonda da immünojenik ve güvenilir olduğu yapılan çalışmalarda gösterilmiştir (25)(26)(27)(28)(29)(30)(31)(32)(33)(34) . Baxter ve ark.…”

Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence

“…44 A further study by Vesikari et al also showed that MenACWY-TT was non-inferior to MenC-CRM197 and was immunogenic in terms of serogroups A, W and Y when administered one thousand toddlers aged 12 to 23 months. 45 In a more recent phase III study conducted in Finland where 1303 healthy toddlers aged 12 to 18 monthsout of the 1554 enrolled -were included in the analysis, Men-ACWY-TT was found immunogenic in 100% of the subjects with hSBA titers > 1:8 and non-inferior to HibMenCY-TT for the serogroups C and Y. 46 Immunogenicity in children Knuf et al established in his study the immunogenicity of four experimental formulations of MenACWY-TT in 268 children aged 3 to 5 years and demonstrated that it was non-inferior to the tetravalent PS vaccine (Mencevax TM , GSK Biologicals).…”

“…45 Group 1 (MMRVCACWY-TT group) received both MenACWY-TT and MMRV at visit one then a second dose of MMRV after 12 weeks, group 2 (ACWY-TT group) received MenACWY-TT at visit one followed with 2 doses of MMRV separated by 6 weeks each, group 3 (MMRV group)received MMRV at visit one then MenC-CRM197 in 6 weeks and a second dose of MMRV 6 weeks later, and group 4 (MenC group) received MenC-CRM197 followed in 6 weeks by 2 doses of MMRV separated by 6 weeks each. The primary objective was to assess the immunogenicity and safety of MenACWY-TT.…”

Risk of febrile seizure after measles–mumps–rubella–varicella vaccine: A systematic review and meta-analysis

“…Twenty-nine clinical trials [26][27][28][29][30][31][32][33][34][35][37][38][39][40][41][42][43][44][45][46][47][48][49][50] reported the incidence of febrile seizure or vaccine related febrile seizure within 0-28, 0-42 or 0-56 days (0-28/42/56 days) after first MMRV vaccine dose in healthy children aged 9-24 months, twenty-five of them [26][27][28][29][30][33][34][35][37][38][39][40][41][42][43][45][46][47][48][49][50] also reported the incidence within a smaller risk window of 7 to 10 days (7-10 days) after vaccination. Children in 17 clinical trials [27][28][29]…”